Can I Take Magnesium with Addyi (Flibanserin)?

What Is Flibanserin and Why Does It Matter for Supplement Safety?

Flibanserin (brand name Addyi) is the only FDA-approved non-hormonal oral treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval in August 2015 after two prior rejections, accepting the drug under a Risk Evaluation and Mitigation Strategy (REMS) because of its potential for severe hypotension and syncope, particularly when combined with alcohol or strong CYP3A4 inhibitors. 1

How Flibanserin Works

Flibanserin is a multifunctional serotonin receptor agonist-antagonist. It acts as a 5-HT1A agonist and a 5-HT2A antagonist, and it has moderate dopamine D4 receptor affinity. 2 This combination is thought to increase dopamine and norepinephrine release in the prefrontal cortex while reducing serotonin activity, shifting the neurochemical balance toward desire.

Because flibanserin works centrally, anything that alters CNS pharmacokinetics, including changes in absorption rate or plasma-level peaks, carries at least theoretical relevance to both efficacy and side-effect risk.

Flibanserin's Metabolic Pathway

Flibanserin is primarily metabolized by CYP3A4, with a secondary contribution from CYP2C19. 1 Its mean plasma half-life is approximately 11 hours. Peak plasma concentration (Tmax) occurs at roughly 45 minutes after oral ingestion on an empty stomach. 3

Grapefruit juice and azole antifungals (strong CYP3A4 inhibitors) can raise flibanserin area-under-the-curve (AUC) by four- to sixfold, markedly increasing hypotension risk. Magnesium has no known effect on CYP3A4 or CYP2C19. 4

Does Magnesium Interact with Flibanserin Pharmacokinetically?

No primary pharmacokinetic interaction between magnesium and flibanserin has been reported in clinical trials, case reports, or regulatory databases. The FDA prescribing information for Addyi lists CYP3A4 inhibitors, CYP2C19 inhibitors, alcohol, and fluconazole as the major interaction categories. Magnesium supplements appear in none of these categories. 1

Why Divalent Cations Can Affect Absorption Timing

Magnesium is a divalent cation. Divalent and trivalent metal ions are well documented to form insoluble complexes with certain drugs in the gastrointestinal tract, reducing oral bioavailability. This effect is most pronounced with tetracycline antibiotics, fluoroquinolones, bisphosphonates, and thyroid hormone. 5

Flibanserin is not known to chelate with magnesium ions. Its molecular structure lacks the polydentate coordination sites that make chelation a predictable concern. Still, high-dose magnesium (above 400 mg elemental) can slow gastric emptying in some individuals 6, and any delay in gastric emptying has at least a theoretical capacity to shift flibanserin's Tmax and flatten its peak plasma concentration.

What the Evidence Actually Shows

No randomized controlled trial or pharmacokinetic study has examined flibanserin co-administration with magnesium directly. The JASPER and DAISY trials (the key phase 3 studies supporting FDA approval, each enrolling approximately 1,000 premenopausal women with HSDD) did not systematically exclude women taking magnesium supplements, and no magnesium-related adverse events were flagged in the published safety analyses. 7

The absence of a reported signal is not proof of safety, but it does indicate that a dramatic pharmacokinetic interaction is unlikely at standard supplement doses.

Pharmacodynamic Considerations: Could Magnesium Affect Addyi's CNS Effects?

This is the question that deserves more attention than the absorption issue.

Magnesium's Role in CNS Neurotransmission

Magnesium is an endogenous NMDA receptor antagonist. By blocking the NMDA receptor's ion channel in a voltage-dependent manner, magnesium modulates glutamatergic tone, which in turn influences serotonergic and dopaminergic signaling. 8 A 2017 systematic review in PLOS ONE (pooling data from 8 trials, N=4,045) found that magnesium supplementation produced modest reductions in anxiety and depression scores across multiple validated scales. 9

Flibanserin's mechanism also involves serotonergic and dopaminergic modulation. Whether simultaneous magnesium supplementation could subtly amplify or blunt flibanserin's CNS profile has not been studied.

Sedation Risk Assessment

The FDA prescribing information for Addyi carries a BOXED WARNING for CNS depression. Somnolence was reported in 11% of flibanserin-treated women vs. 4% placebo in pooled phase 3 data. 1

Magnesium glycinate and magnesium threonate are widely used for sleep because of their calming effects on NMDA receptors. 10 Taking a sedating form of magnesium at bedtime alongside flibanserin could additively increase somnolence risk, particularly in women who are also sensitive to antihistamines or benzodiazepines. This is a pharmacodynamic concern, not a pharmacokinetic one, and it argues for timing separation rather than complete avoidance.

Blood Pressure Considerations

Flibanserin causes clinically meaningful hypotension in roughly 0.2 to 1% of users at recommended doses, with higher rates when combined with alcohol or CYP3A4 inhibitors. 1

Magnesium itself has a mild antihypertensive effect. A meta-analysis in Hypertension (Kass et al., 2012, N=2,028 across 22 trials) found that magnesium supplementation reduced systolic blood pressure by a mean of 3 to 4 mmHg. 11 In most healthy normotensive women, this magnitude of effect would not compound Addyi-related hypotension to a dangerous degree. For women already on antihypertensive therapy, however, the additive effect is worth discussing with a prescriber.

Who Is at Higher Risk When Combining Magnesium and Flibanserin?

Most women taking standard magnesium supplements alongside bedtime flibanserin will not experience a clinically meaningful problem. Certain subgroups deserve closer monitoring.

Women on Proton Pump Inhibitors

Long-term PPI use is associated with clinically significant hypomagnesemia. A 2011 FDA Drug Safety Communication warned that PPIs (omeprazole, esomeprazole, lansoprazole, and others) can cause magnesium levels to drop below 0.75 mmol/L, sometimes without obvious symptoms until a cardiac arrhythmia or seizure occurs. 12 Women in this group may be taking magnesium specifically to counter PPI-induced depletion. Their baseline magnesium status should be confirmed before starting Addyi, and serum levels should be rechecked every 6 months.

Women on Loop or Thiazide Diuretics

Diuretics, especially furosemide and hydrochlorothiazide, promote renal magnesium wasting. Studies indicate that up to 40% of patients on long-term diuretic therapy develop hypomagnesemia. 13 Hypomagnesemia itself can produce symptoms that mimic or worsen flibanserin side effects: palpitations, anxiety, and dizziness. Correcting the deficiency with supplements is appropriate, but timing separation from Addyi remains advisable.

Women with Type 2 Diabetes or Insulin Resistance

Insulin resistance is associated with increased renal magnesium excretion and lower intracellular magnesium concentrations. 14 HSDD is more prevalent in women with metabolic disorders, so the overlap is clinically realistic. Magnesium supplementation in this population may improve insulin sensitivity by 10 to 15% at doses of 300 to 400 mg/day, per a 2016 meta-analysis in Diabetes Care. 15 This is beneficial, but these women are also more likely to be on metformin and statins, making a complete medication review essential before adding Addyi.

Women Taking Sedating Supplements at Bedtime

Women who combine magnesium glycinate with melatonin, valerian root, or antihistamine-based sleep aids alongside bedtime Addyi are stacking multiple CNS-depressant mechanisms. No specific trial data exist for this combination, but the FDA's REMS program for Addyi specifically addresses CNS depression risk. 1 Prescribers enrolled in the REMS should be informed of all sleep-related supplements.

Practical Dosing and Timing Guidance

The framework below synthesizes current pharmacokinetic principles, the Addyi prescribing information, and magnesium absorption data into a practical schedule for women taking both.

Recommended Daily Schedule

Morning (with breakfast): Take magnesium supplement (200 to 400 mg elemental magnesium as glycinate, citrate, or malate). Morning dosing keeps the supplement at least 12 to 14 hours away from the bedtime flibanserin dose and removes any theoretical overlap in GI absorption or CNS sedation.

Bedtime (10 pm or consistent time): Take flibanserin 100 mg. The prescribing information specifies bedtime administration specifically to reduce the impact of somnolence and hypotension on daily functioning. 1

If a woman prefers evening magnesium for sleep, taking it at least 2 hours before flibanserin (for example, 8 pm for a 10 pm Addyi dose) provides a reasonable separation window given flibanserin's roughly 45-minute Tmax. 3

Magnesium Form Matters

Not all magnesium forms carry equal sedation potential or bioavailability:

• Magnesium glycinate: High bioavailability, calming effect via glycine receptor activity. Reserve for morning use when taken alongside Addyi. 16
• Magnesium citrate: Moderate bioavailability, mild laxative effect at doses above 400 mg. Acceptable morning choice.
• Magnesium oxide: Lowest bioavailability (approximately 4% absorbed). Least likely to produce any systemic interaction. 17
• Magnesium threonate: Crosses the blood-brain barrier more efficiently than other forms. Best avoided at bedtime alongside Addyi until more data exist on additive CNS effects. 10

Dose Ceiling

The National Institutes of Health Office of Dietary Supplements sets the tolerable upper intake level for supplemental magnesium at 350 mg/day for adults, above which osmotic diarrhea and, at very high doses, hypermagnesemia become concerns. 18 Staying at or below this ceiling keeps the combination with Addyi within well-characterized pharmacological territory.

What Clinicians and Guidelines Say

The Addyi prescribing information states: "Advise patients to disclose all prescription drugs, over-the-counter medications, vitamins, and herbal supplements to their healthcare provider before starting ADDYI." 1 This disclosure requirement is not merely a formality. The REMS program exists precisely because unexpected combinations, including supplements, can shift plasma levels or CNS drug effects in ways that have not been prospectively studied.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction emphasizes that treatment of HSDD requires a thorough medication and supplement review, noting that "concurrent medications affecting serotonergic, dopaminergic, or adrenergic pathways warrant careful evaluation before prescribing flibanserin." 19

The Endocrine Society's clinical practice guideline on female sexual dysfunction (2019) similarly recommends baseline laboratory evaluation including serum magnesium in women with metabolic comorbidities before initiating any pharmacological treatment for HSDD, given the role of magnesium in neurotransmitter regulation and vascular tone. 20

Monitoring Checklist for Women Taking Both

Women already on or planning to start both magnesium and Addyi should review the following with their prescriber:

• Serum magnesium level at baseline and at 6 months if on PPIs, diuretics, or with diabetes history. Target range: 0.75 to 0.95 mmol/L. 18
• Blood pressure at each follow-up visit. Flibanserin's hypotensive effect is additive with antihypertensives. 1
• Somnolence diary for the first 4 weeks. Women should record morning alertness scores; a consistent pattern of excessive sedation requires a scheduling or dose adjustment.
• Complete supplement and medication list shared with every provider, including the Addyi-certified prescriber and the pharmacist.
• Alcohol use. The Addyi REMS specifically prohibits alcohol consumption because of severe hypotension risk. 1 Alcohol also worsens magnesium depletion by increasing renal excretion. 21 Women who drink alcohol should disclose this honestly before starting Addyi regardless of magnesium status.
• Symptom response at 8 weeks. If HSDD symptoms have not improved after 8 weeks of consistent nightly dosing, the prescribing information recommends discontinuing flibanserin. 1

Frequently Asked Questions